Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announces that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow’s portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes.
Read the full article: Harrow Announces Closing of Acquisition of Melt Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2025/11/18/3189844/0/en/Harrow-Announces-Closing-of-Acquisition-of-Melt-Pharmaceuticals.html